Exemestane and Everolimus combination treatment of hormone receptor positive, HER2 negative metastatic breast cancer: A retrospective study of 9 cancer centers in the Campania Region (Southern Italy) focused on activity, efficacy and safety
Ferdinando Riccardi(Ospedale Antonio Cardarelli), Michele Orditura(University of Campania "Luigi Vanvitelli"), O Marano, Anna Diana(University of Campania "Luigi Vanvitelli"), Fortunato Ciardiello(University of Campania "Luigi Vanvitelli"), Antonio Febbraro(Fatebenefratelli Hospital), Sabino De Placido, Rossella Lauria, Giuseppe Colantuoni(Azienda Ospedaliera S.Giuseppe Moscati), Raffaele Addeo(George Moore Community Clinic), Carmela Mocerino(Ospedale Antonio Cardarelli), Pasquale Incoronato, Giacomo Carten�(Fatebenefratelli Hospital), Francesco Nuzzo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale")
Cited by 14
Related Papers
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
|The Lancet Oncology|2016|1k
Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and <i>RAS</i> Mutations in Colorectal Cancer
|Journal of Clinical Oncology|2015|795